NO20055607L - Antilosemiddel solidifiseringsprosess - Google Patents

Antilosemiddel solidifiseringsprosess

Info

Publication number
NO20055607L
NO20055607L NO20055607A NO20055607A NO20055607L NO 20055607 L NO20055607 L NO 20055607L NO 20055607 A NO20055607 A NO 20055607A NO 20055607 A NO20055607 A NO 20055607A NO 20055607 L NO20055607 L NO 20055607L
Authority
NO
Norway
Prior art keywords
antelope
solidification process
organic
inorganic compound
solvent solidification
Prior art date
Application number
NO20055607A
Other languages
English (en)
Other versions
NO20055607D0 (no
Inventor
Robert Michael Geertman
Cornelis Elisabeth Johann Lare
Wridzer Jan Willem Bakker
Marianne Frederika Reedijk
Jozef Johannes Maria Baltussen
Gerrald Bargeman
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33418418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055607(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO20055607L publication Critical patent/NO20055607L/no
Publication of NO20055607D0 publication Critical patent/NO20055607D0/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D3/00—Halides of sodium, potassium or alkali metals in general
    • C01D3/22—Preparation in the form of granules, pieces, or other shaped products
    • C01D3/24—Influencing the crystallisation process
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Glanulating (AREA)
  • Colloid Chemistry (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

Forehggende oppfirmelse omhandler en antiløsemiddel sohdifiseringsprosess hvori et flytende medium som omfatter minst én organisk eller uorganisk forbindelse som skal solidifiseres blfr tvunget gjermom en membran irm i ett eller flere antiløsemidler, eller hvori ett eller flere antiløsemidler blir tvunget gjermom en membran irm i et flytende medium som omfatter minst én organisk eller uorganisk forbindelse som skal solidifiseres, hvilket gir en sammensetning som omfatter faste partikler som omfatter nevnte organiske og/eller uorganiske forbindelse(r).
NO20055607A 2003-04-29 2005-11-28 Antilosemiddel solidifiseringsprosess NO20055607D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46676103P 2003-04-29 2003-04-29
PCT/EP2004/004506 WO2004096405A1 (en) 2003-04-29 2004-04-28 Antisolvent solidification process

Publications (2)

Publication Number Publication Date
NO20055607L true NO20055607L (no) 2005-11-28
NO20055607D0 NO20055607D0 (no) 2005-11-28

Family

ID=33418418

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055607A NO20055607D0 (no) 2003-04-29 2005-11-28 Antilosemiddel solidifiseringsprosess

Country Status (23)

Country Link
US (4) US20060182808A1 (no)
EP (1) EP1620193B1 (no)
JP (1) JP5207432B2 (no)
KR (1) KR20060006949A (no)
CN (1) CN100434133C (no)
AR (1) AR044140A1 (no)
AT (1) ATE406946T1 (no)
AU (1) AU2004234057A1 (no)
BR (1) BRPI0409860A (no)
CA (1) CA2523883C (no)
CL (1) CL2004000912A1 (no)
DE (1) DE602004016311D1 (no)
ES (1) ES2312996T3 (no)
HK (1) HK1088268A1 (no)
IL (1) IL171613A (no)
MX (1) MXPA05011626A (no)
MY (1) MY141189A (no)
NO (1) NO20055607D0 (no)
NZ (1) NZ543772A (no)
RU (1) RU2339364C2 (no)
TW (1) TW200500095A (no)
WO (1) WO2004096405A1 (no)
ZA (1) ZA200509597B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475845B2 (en) * 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
US20100183725A1 (en) * 2005-07-15 2010-07-22 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
US7942990B2 (en) 2006-12-18 2011-05-17 Daicel Chemical Industries, Ltd. Hybrid inflator
EP2124633B1 (en) * 2007-01-22 2012-03-07 Cargill, Incorporated Method of producing purified rebaudioside a compositions using solvent/antisolvent crystallization
GB0705159D0 (en) * 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
FI120527B (fi) * 2007-06-18 2009-11-30 Crisolteq Oy Talteenottomenetelmä
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
TWI466709B (zh) * 2011-07-20 2015-01-01 Nat Univ Chung Hsing From the original berry Wolfberry a liquid - liquid freezing method for separation of high purity theaflavins palmitate Maize
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9452930B2 (en) * 2013-11-04 2016-09-27 New Jersey Institute Of Technology System and method for continuous polymer coating of particles
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT108368B (pt) * 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN106853295A (zh) * 2015-12-09 2017-06-16 北大方正集团有限公司 一种基于膜分散的结晶方法
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10881123B2 (en) * 2017-10-27 2021-01-05 Frito-Lay North America, Inc. Crystal morphology for sodium reduction
JP6761560B2 (ja) * 2018-06-14 2020-09-23 日揮株式会社 晶析装置及び晶析方法
CN112969466A (zh) * 2018-12-28 2021-06-15 四川科伦药物研究院有限公司 制备黄体酮颗粒物的方法、所得黄体酮颗粒物及其注射剂
CN111234431A (zh) * 2020-03-31 2020-06-05 宁夏颐星新材料科技有限公司 一种消泡型聚乙烯醇粉末的生产工艺
GB202004824D0 (en) * 2020-04-01 2020-05-13 Naturbeads Ltd Biopolymer particle preparation
GB202011836D0 (en) 2020-07-30 2020-09-16 Micropore Tech Limited Crystallisation methods
CN115777906A (zh) * 2021-09-10 2023-03-14 吉林大学 氯化钠纳微米粒子及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716453B1 (fr) * 1994-02-22 1996-03-29 Rhone Poulenc Agrochimie Procédé de sulfinylation de composés hétérocycliques.
US4089843A (en) * 1976-09-20 1978-05-16 The Upjohn Company Precipitating polymers in powder form
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
JPH0672528B2 (ja) * 1985-07-16 1994-09-14 三信工業株式会社 船舶のエンジン
US5269926A (en) * 1991-09-09 1993-12-14 Wisconsin Alumni Research Foundation Supported microporous ceramic membranes
FR2658498B1 (fr) * 1990-02-19 1992-05-15 Atochem Particules de chlorure de magnesium a structure tronc conique, composante catalytique supportee sur ces particules, polyolefines obtenues a partir de cette composante catalytique, procedes de fabrication de ces produits.
JP2555475B2 (ja) * 1990-10-16 1996-11-20 工業技術院長 無機質微小球体の製造方法
JP2816597B2 (ja) * 1990-11-28 1998-10-27 富士写真フイルム株式会社 溶液の均一混合装置および弾性体多孔膜
IE71202B1 (en) * 1990-12-17 1997-02-12 Akzo Nv Progestagen-only contraceptive
WO1993000156A1 (en) * 1991-06-29 1993-01-07 Miyazaki-Ken Monodisperse single and double emulsions and production thereof
EP0617612B1 (en) * 1991-12-18 1997-09-10 Warner-Lambert Company A process for the preparation of a solid dispersion
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
CA2175814C (en) * 1993-11-08 2000-01-04 Stephane Fabrice Rouanet Antiperspirants containing aerogel particles
JP3492787B2 (ja) * 1994-04-15 2004-02-03 信越化学工業株式会社 固形製剤のコーティング用水性エマルジョンの濃縮方法
US6387399B1 (en) * 1994-12-02 2002-05-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulated bioactive agents and method of making
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5876480A (en) * 1996-02-20 1999-03-02 The United States Of America As Represented By The Secretary Of The Navy Synthesis of unagglomerated metal nano-particles at membrane interfaces
GB9610955D0 (en) * 1996-05-24 1996-07-31 Hercules Inc Sizing composition
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable
US5879715A (en) * 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
DK1071402T3 (da) * 1998-04-09 2007-02-19 Hoffmann La Roche Fremgangsmåde til af partikler med (sub)mikronstörrelse ved oplösning i komprimeret gas og overfladeaktive stoffer
SE9801287D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
US6113795A (en) * 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IN191236B (no) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6780507B2 (en) * 2000-02-09 2004-08-24 Analytical Research Systems, Inc. Hydrocapsules and method of preparation thereof
US6623761B2 (en) * 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
ATE336231T1 (de) * 2001-08-29 2006-09-15 Dow Global Technologies Inc Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung
RS29104A (en) * 2001-10-10 2006-12-15 Boehringer Ingelheim Pharmaceuticals Inc. Powder processing with pressurized gaseous fluids
US6890592B2 (en) * 2002-03-13 2005-05-10 Appleton Papers Inc. Uniform microcapsules
US6966990B2 (en) * 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing

Also Published As

Publication number Publication date
NZ543772A (en) 2009-05-31
CA2523883A1 (en) 2004-11-11
CA2523883C (en) 2012-01-03
RU2005136983A (ru) 2006-03-20
EP1620193B1 (en) 2008-09-03
US20060182808A1 (en) 2006-08-17
MY141189A (en) 2010-03-31
AU2004234057A1 (en) 2004-11-11
CN100434133C (zh) 2008-11-19
MXPA05011626A (es) 2006-01-23
TW200500095A (en) 2005-01-01
IL171613A (en) 2010-02-17
RU2339364C2 (ru) 2008-11-27
US20120232296A1 (en) 2012-09-13
CL2004000912A1 (es) 2005-02-04
US20110268806A1 (en) 2011-11-03
BRPI0409860A (pt) 2006-05-16
US20130131029A1 (en) 2013-05-23
CN1780670A (zh) 2006-05-31
JP2006524565A (ja) 2006-11-02
ATE406946T1 (de) 2008-09-15
AR044140A1 (es) 2005-08-24
ES2312996T3 (es) 2009-03-01
HK1088268A1 (en) 2006-11-03
DE602004016311D1 (de) 2008-10-16
KR20060006949A (ko) 2006-01-20
EP1620193A1 (en) 2006-02-01
JP5207432B2 (ja) 2013-06-12
WO2004096405A1 (en) 2004-11-11
ZA200509597B (en) 2006-12-27
NO20055607D0 (no) 2005-11-28

Similar Documents

Publication Publication Date Title
NO20055607L (no) Antilosemiddel solidifiseringsprosess
DE60232468D1 (de) Ente und damit zusammenhängende verfahren
CY1111817T1 (el) Απομακρυνση του διαλυτη με μια διαδικασια προσθιας οσμωσης
ATE324176T1 (de) Funktionalisierte halogenierte polymere für die mikroverkapselung
EA201070610A1 (ru) Способы получения и применения вспомогательного газа
NO20042321L (no) Partikkelfjerningssystem
NO20065084L (no) Interferon-alfa polypeptider og konjugater
SMP200900097B (it) Sistema e metodo per rimuovere biossido di carbonio da un'atmosfera e termostato globale che utilizza il medesimo
HK1082430A1 (en) Method for the preparation of molecular complexes
ATE556788T1 (de) Herstellung pharmazeutischer wirkstoffpartikel unter verwendung fokussierter akustischer energie
AR052827A1 (es) Composicion veterinaria inyectable
DE60129137D1 (de) Modulierung durch il-tif/interleukin-21
FI20031642A0 (fi) Oksapuu-uutteiden uusi käyttö
TW200714688A (en) Method for regenerating fluorescent material and fluorescent lamp
CY1115474T1 (el) Χρωματογραφικη μεθοδος
DE10124166B8 (de) Verfahren zum Kühlen von Anlagenkomponenten, die von fließfähigen Medien beaufschlagt werden
BRPI0412469A (pt) sistema de comunicação, computador de filtro de mensagens peer-to-peer e processo para o processamento pra o processamento de uma mensagem peer-to-peer
EA200501698A1 (ru) Противовспенивающие композиции
ATE477533T1 (de) Polymorphismus zur laufzeit
WO2018217789A3 (en) COMPOSITIONS, METHODS, KITS AND MOLECULAR ANALYSIS DEVICES
RU99127483A (ru) Способ бальзамирования анатомических препаратов силоксановыми композициями
SE0702711L (sv) Ny kemisk substans lämplig för användning som mjukgörare i sprängämnes- och drivmedelsblandningar
TH68562A (th) กรรมวิธีการทำให้เป็นของแข็งแบบต่อต้านตัวทำละลาย
McMath Cutting the cost of tunnel vision
RU2004117239A (ru) Способ торможения вертикальных гидроагрегатов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application